Methylation alteration of
SHANK1
cancer methylation alteration
diagnostic biomarkers
predictive biomarkers
prognostic biomarkers
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
13 Aug 2019
13 Aug 2019
Historique:
received:
14
03
2019
accepted:
21
06
2019
entrez:
28
8
2019
pubmed:
28
8
2019
medline:
28
8
2019
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the clonal expansion of malignant B cells. To predict the clinical course of the disease, the identification of diagnostic biomarkers is urgently needed. Aberrant methylation patterns may predict CLL development and its course, being very early changes during carcinogenesis. Our aim was to identify CLL specific methylation patterns and to evaluate whether methylation aberrations in selected genes are associated with changes in gene expression. Here, by performing a genome-wide methylation analysis, we identified several CLL-specific methylation alterations. We focused on the most altered one, at a CpG island located in the body of
Identifiants
pubmed: 31452839
doi: 10.18632/oncotarget.27080
pii: 27080
pmc: PMC6697638
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4987-5002Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflict of interest.
Références
Mol Cancer Res. 2003 Mar;1(5):346-61
pubmed: 12651908
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Leukemia. 2006 Jul;20(7):1326-9
pubmed: 16688227
Cancer Cell. 2006 Jun;9(6):435-43
pubmed: 16766263
Cancer Res. 2007 Feb 15;67(4):1419-23
pubmed: 17308078
Cancer Res. 2007 Feb 15;67(4):1424-9
pubmed: 17308079
J Neurochem. 2007 Jun;101(5):1380-91
pubmed: 17419801
Genome Res. 2008 Sep;18(9):1518-29
pubmed: 18577705
Blood. 2009 Apr 30;113(18):4188-96
pubmed: 19015397
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):671-8
pubmed: 19139413
Nat Biotechnol. 2009 Apr;27(4):361-8
pubmed: 19329998
Genome Res. 2009 Jul;19(7):1165-74
pubmed: 19494038
Eur J Haematol. 2009 Dec 1;83(6):541-9
pubmed: 19682311
Nature. 2010 Jul 8;466(7303):253-7
pubmed: 20613842
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Oncogene. 2011 Aug 4;30(31):3404-15
pubmed: 21383689
PLoS One. 2011 Apr 19;6(4):e18844
pubmed: 21526191
Nature. 2011 Nov 3;479(7371):74-9
pubmed: 21964334
Genome Res. 2012 Feb;22(2):246-58
pubmed: 22156296
PLoS One. 2012;7(3):e33213
pubmed: 22479372
J Clin Oncol. 2012 Jul 10;30(20):2483-91
pubmed: 22564988
BMC Bioinformatics. 2012 May 08;13:86
pubmed: 22568884
PLoS One. 2012;7(7):e41361
pubmed: 22848472
Nat Genet. 2012 Nov;44(11):1236-42
pubmed: 23064414
Epigenetics. 2013 Feb;8(2):138-48
pubmed: 23321535
Cancer Prev Res (Phila). 2013 Jul;6(7):656-65
pubmed: 23694962
Nat Genet. 2013 Jul;45(7):836-41
pubmed: 23708189
Nat Rev Genet. 2013 Jul;14(7):496-506
pubmed: 23774734
Biochim Biophys Acta. 2013 Nov;1829(11):1161-74
pubmed: 23938249
Genome Res. 2014 Feb;24(2):212-26
pubmed: 24265505
Nat Rev Genet. 2014 Feb;15(2):121-32
pubmed: 24434847
Biomed Res Int. 2014;2014:435983
pubmed: 24967369
Leukemia. 2015 Mar;29(3):598-605
pubmed: 25151957
Nat Methods. 2014 Nov;11(11):1138-1140
pubmed: 25262207
Blood Cancer J. 2015 Apr 10;5:e303
pubmed: 25860294
Nat Genet. 2015 Jul;47(7):746-56
pubmed: 26053498
Epigenomics. 2016 Jan;8(1):55-66
pubmed: 26679037
J Intern Med. 2016 Apr;279(4):347-57
pubmed: 26709197
Nat Genet. 2016 Mar;48(3):253-64
pubmed: 26780610
Epigenetics. 2016 Aug 2;11(8):588-602
pubmed: 27245242
Oncotarget. 2017 Jun 27;8(26):41890-41902
pubmed: 28514750
BMC Genomics. 2017 Sep 13;18(1):728
pubmed: 28903739
Genet Epidemiol. 2018 Feb;42(1):20-33
pubmed: 29034560
Dis Markers. 2017;2017:3726595
pubmed: 29038612
Int J Cancer. 2018 Aug 15;143(4):907-920
pubmed: 29542109
Oncotarget. 2018 Feb 12;9(17):13807-13821
pubmed: 29568396
Adv Immunol. 1995;58:345-416
pubmed: 7537936